Compare Neurocrine Biosciences Inc (NBIX) vs Southern Company (SO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Southern Company — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Southern Company trades at $88.67 (market cap $102.37B). The key difference: Southern Company is far larger — about 6.5× Neurocrine Biosciences Inc's market cap, and Southern Company pays a 3.42% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SO | |
|---|---|---|
Market Cap | $15.77B | $102.37B |
Sector | Health | Utilities |
52-Week High | $185.50 | $99.72 |
52-Week Low | $123.10 | $84.08 |
Enterprise Value | $15.78B | $176.47B |
Dividend Yield | — | 3.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Southern Company
Southern Company is a U.S. energy company with electric and gas utility businesses. Its power generation portfolio includes natural gas, nuclear, renewable, and other energy sources.
Read more on SO →
